about
Prime-boost approaches to tuberculosis vaccine developmentOrthopoxvirus genome evolution: the role of gene lossA novel replication-competent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination.Direct presentation is sufficient for an efficient anti-viral CD8+ T cell response.Induction of Potent and Long-Lived Antibody and Cellular Immune Responses in the Genitorectal Mucosa Could be the Critical Determinant of HIV Vaccine Efficacy.Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccinesPreclinical studies of a modified vaccinia virus Ankara-based HIV candidate vaccine: antigen presentation and antiviral effect.Unpolarized release of vaccinia virus and HIV antigen by colchicine treatment enhances intranasal HIV antigen expression and mucosal humoral responses.The influence of delivery vectors on HIV vaccine efficacyNovel mucosal DNA-MVA HIV vaccination in which DNA-IL-12 plus cholera toxin B subunit (CTB) cooperates to enhance cellular systemic and mucosal genital tract immunityImproving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein.Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial.IL-12 and GM-CSF in DNA/MVA immunizations against HIV-1 CRF12_BF Nef induced T-cell responses with an enhanced magnitude, breadth and quality.Current progress in the development of a prophylactic vaccine for HIV-1.Induced bronchus-associated lymphoid tissue serves as a general priming site for T cells and is maintained by dendritic cells.A novel candidate HIV vaccine vector based on the replication deficient Capripoxvirus, Lumpy skin disease virus (LSDV)Targeting OX40 promotes lung-resident memory CD8 T cell populations that protect against respiratory poxvirus infectionA comparative analysis of HIV-specific mucosal/systemic T cell immunity and avidity following rDNA/rFPV and poxvirus-poxvirus prime boost immunisationsA new rabies vaccine based on a recombinant ORF virus (parapoxvirus) expressing the rabies virus glycoprotein.Recent advances in delivery systems for anti-HIV1 therapy.Differential immunogenicity of vaccinia and HIV-1 components of a human recombinant vaccine in mucosal and blood compartments.The 3'-to-5' exonuclease activity of vaccinia virus DNA polymerase is essential and plays a role in promoting virus genetic recombination.MHC-I-restricted epitopes conserved among variola and other related orthopoxviruses are recognized by T cells 30 years after vaccination.Genetic heterologous prime-boost vaccination strategies for improved systemic and mucosal immunity.Archaeal lipid mucosal vaccine adjuvant and delivery system.Capsid-incorporation of antigens into adenovirus capsid proteins for a vaccine approach.Recombinant influenza vaccines.Modified Vaccinia Virus Ankara Vector Induces Specific Cellular and Humoral Responses in the Female Reproductive Tract, the Main HIV Portal of Entry.Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies.Intergenic region 3 of modified vaccinia ankara is a functional site for insert gene expression and allows for potent antigen-specific immune responses.Infectivity of attenuated poxvirus vaccine vectors and immunogenicity of a raccoonpox vectored rabies vaccine in the Brazilian Free-tailed bat (Tadarida brasiliensis).Characterization of ectromelia virus deficient in EVM036, the homolog of vaccinia virus F13L, and its application for rapid generation of recombinant viruses.Differential CD4+ versus CD8+ T-cell responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates.
P2860
Q27024526-6C32436F-9D6F-4703-83C3-661FCFFA520FQ28744298-1863AE8D-2B0F-412C-B0A9-173511D398EFQ33401609-1B4F1221-5483-450A-924C-B563A8712872Q33532640-707B04B2-119F-4D00-91F5-5BFB2A132835Q33611645-C6D4294B-9A60-4A78-BC62-FF6F232A04D1Q33653229-3F8A2559-5B82-476D-8308-876D1C9A03A3Q33826983-4B6EE656-B859-4C66-84BD-C6B2C0F64DC2Q34026061-3A0AE91A-7E04-44C4-98F1-7B580DB62EC0Q34077543-F78104CA-F506-4DA0-AC31-BBC015726B54Q34172564-C791FEC7-1396-4503-BE84-F36B445D561BQ34182371-217D0945-9824-4DE2-9888-D82BFE6B20D2Q34259027-8D89472B-279C-4FCF-B785-ABE0C4259253Q34289072-6F699A75-1C65-4DF1-90E8-763575A3B8BDQ34502108-80C9DB98-B176-4840-925F-6A1499548DFCQ35013206-5CA7AF32-FA9E-4783-8A71-1AB551EA1B7DQ35053133-7ED1ABAC-D757-4C9C-BBED-35084E9D6083Q35193006-5722B20B-DB7E-4543-9768-3DEB52E86198Q35628697-9F034142-BDC4-47D4-A4ED-2F361BB3CDEAQ36559952-AEE386CF-AB1A-41CB-8CB5-58FDCA93C8DFQ36761854-5A90E0CA-8379-4EE5-87F0-9A2D6D1BB6B9Q36943319-0D07802C-4EA9-41BF-B4FA-81EC2D4B009CQ37157260-CC56DE75-42B6-4FA1-85BA-73C3B2A3A8D4Q37443937-0677C845-FB25-4D3A-A982-5B33A966E049Q37590335-BD1A8867-B69B-442E-AE75-3FD7280E0F30Q37724863-A29B3BE9-4B04-4DF7-8B0C-E90A15346C2DQ37806749-48FE33E8-38B7-4E4C-9121-08843417F318Q38076422-D2A31D55-E810-4B3B-B0E6-56739F6CAF5AQ38369341-4A790B2F-7AC0-41F5-90FC-C17F96C87621Q38461061-DF6BC9C6-6463-4F7C-93D0-277C7F21B3C1Q39703820-096236A3-FA0D-4AA4-B4B4-835F21BF2FF6Q40533280-CD9A7AC2-6EE2-430E-806D-2A9B309448F1Q41649964-0061CDC4-42D6-414A-A2CC-5323B552B03FQ42100401-DC803B4B-9D64-4167-89F7-AA5132665970
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Recombinant poxviruses as mucosal vaccine vectors.
@ast
Recombinant poxviruses as mucosal vaccine vectors.
@en
type
label
Recombinant poxviruses as mucosal vaccine vectors.
@ast
Recombinant poxviruses as mucosal vaccine vectors.
@en
prefLabel
Recombinant poxviruses as mucosal vaccine vectors.
@ast
Recombinant poxviruses as mucosal vaccine vectors.
@en
P356
P1476
Recombinant poxviruses as mucosal vaccine vectors.
@en
P2093
M Magdalena Gherardi
Mariano Esteban
P304
P356
10.1099/VIR.0.81181-0
P407
P577
2005-11-01T00:00:00Z